BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/7/2019 7:09:17 AM | Browse: 833 | Download: 1076
 |
Received |
|
2019-03-17 09:21 |
|
Peer-Review Started |
|
2019-03-18 08:48 |
|
To Make the First Decision |
|
2019-05-14 01:13 |
|
Return for Revision |
|
2019-05-15 00:58 |
|
Revised |
|
2019-05-23 14:03 |
|
Second Decision |
|
2019-06-26 10:01 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-07-03 01:15 |
|
Articles in Press |
|
2019-07-03 01:15 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-08-06 02:30 |
|
Publish the Manuscript Online |
|
2019-08-07 07:09 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Elena De Mattia, Erika Cecchin, Michela Guardascione, Luisa Foltran, Tania Di Raimo, Francesco Angelini, Mario Rosario D'Andrea and Giuseppe Toffoli |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| European Union’s Horizon 2020 Research and Innovation Programme |
668353 |
|
| Corresponding Author |
Elena De Mattia, PhD, Postdoc, Experimental and Clinical Pharmacology Unit, CRO Aviano National Cancer Institute, IRCCS, via F. Gallini 2, Aviano (PN) 33081, Italy., Aviano 33081, Pordenone, Italy. edemattia@cro.it |
| Key Words |
Hepatocellular carcinoma; Pharmacogenetics; Genetic markers; Sorafenib; Regorafenib; Immune checkpoint inhibitors |
| Core Tip |
Patients with advanced hepatocellular carcinoma (HCC) have few effective therapeutic options. Although multikinase inhibitors — such as sorafenib as first-line treatment and regorafenib in sorafenib progressors — show some overall survival benefit, unmet needs persist in the treatment of advanced HCC. Particularly, the identification of potential prognostic and predictive biomarkers for better stratifying and personalizing the treatment remains a challenge. Germ-line polymorphisms have been suggested to contribute significantly to inter-individual variability in HCC therapy outcome in terms of both toxicity and effectiveness, opening new avenues for pharmacogenetic investigation. |
| Publish Date |
2019-08-07 07:09 |
| Citation |
De Mattia E, Cecchin E, Guardascione M, Foltran L, Di Raimo T, Angelini F, D’Andrea M, Toffoli G. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol 2019; 25(29): 3870-3896 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i29/3870.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i29.3870 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
